Santiago Escrivá-de-Romaní

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

Hope S. Rugo, Seock‐Ah Im, Fátima Cardoso et al. · JAMA Oncology · 2021 · 336 citations · Full text

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

José Manuel Pérez-García, Géraldine Gebhart, Manuel Ruíz Borrego et al. · The Lancet Oncology · 2021 · 152 citations

Breast Oncology, Medicine, Chemotherapy De-escalation +5

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

Nadia Harbeck, Eva Ciruelos, Guy Jérusalem et al. · Nature Medicine · 2024 · 141 citations · Full text

Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

Eva Ciruelos, Patricia Villagrasa, Tomás Pascual et al. · Clinical Cancer Research · 2020 · 111 citations

LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer

C. Saura Manich, Joyce O’Shaughnessy, Philippe Aftimos et al. · Annals of Oncology · 2021 · 103 citations

Metastatic Breast Cancer, Breast Oncology, Medicine +7